SCHEDULE 13G: Trails Edge Funds Disclose 5.1% Stake in Inhibikase

Trails Edge Capital Partners and affiliated entities report a 5.1% passive beneficial ownership in Inhibikase Therapeutics, Inc.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai (collectively, the "Filers") have filed a Schedule 13G.
• The Filers beneficially own an aggregate of 6,145,198 shares of Common Stock of Inhibikase Therapeutics, Inc.
• This ownership represents 5.1% of the outstanding shares of Inhibikase Therapeutics, Inc.
• The ownership percentage is calculated based on 120,899,650 shares outstanding, as reported in the Issuer's Final Prospectus dated November 20, 2025.
• Trails Edge Biotechnology Master Fund, LP directly holds these 6,145,198 shares.
• Trails Edge Capital Partners, LP, as the investment manager, and Ortav Yehudai, as Chief Investment Officer, are deemed to beneficially own these securities due to their voting and investment discretion.
• The securities were acquired and are held for investment purposes and not with the intent to change or influence control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant passive ownership stake by an institutional investor, which can be interpreted as a vote of confidence without implying active engagement or control.

Positives

• A significant institutional investor, Trails Edge Biotechnology Master Fund, LP, has taken a 5.1% stake in Inhibikase Therapeutics, Inc., which can be interpreted as a signal of confidence in the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the issuer or the reporting persons regarding the company's future performance or strategic direction.

Management Comments

• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

A 5.1% passive stake by an investment fund in a biotechnology company like Inhibikase Therapeutics, Inc. is a routine disclosure for institutional investors. It suggests an investment thesis based on the company's potential within the biotechnology sector, which often relies on institutional capital for research, development, and market validation.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional ownership stake may be viewed positively, potentially enhancing market confidence and liquidity for Inhibikase Therapeutics, Inc. shares.
• Management: The company's management is now aware of a significant passive investor on its cap table, which is a standard aspect of public company operations.

Key Dates

Recommendation

The Schedule 13G filing indicates that Trails Edge Capital Partners and its affiliates have acquired a 5.1% passive stake in Inhibikase Therapeutics, Inc. While this signals institutional interest and potential confidence in the company, the filing itself does not provide new operational or financial data to warrant a change in investment thesis. Investors should continue to hold their positions and monitor the company's fundamental performance and future disclosures.

Keywords

Inhibikase Therapeutics, Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Schedule 13G, beneficial ownership, common stock, biotechnology, institutional investment